Venrock spreads HAE bets

Why Venrock picked Attune for its latest oral HAE investment

Venrock is broadening its portfolio of oral hereditary angioedema therapy investments by leading a $23 million series B round that will allow Attune Pharmaceuticals to move its lead plasma kallikrein (KLKB1) inhibitor into Phase II testing.

Venrock was an early investor in HAE

Read the full 424 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE